BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32562877)

  • 1. Efficacy of Reslizumab Treatment in Exacerbation-Prone Patients with Severe Eosinophilic Asthma.
    Wechsler ME; Hickey L; Garin M; Chauhan A
    J Allergy Clin Immunol Pract; 2020; 8(10):3434-3442.e4. PubMed ID: 32562877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intravenously administered reslizumab on spirometric lung age in patients with moderate-to-severe eosinophilic asthma.
    Carr WW; McDonald M; Meizlik P
    Allergy Asthma Proc; 2019 Jul; 40(4):240-249. PubMed ID: 31262379
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials.
    Bernstein JA; Virchow JC; Murphy K; Maspero JF; Jacobs J; Adir Y; Humbert M; Castro M; Marsteller DA; McElhattan J; Hickey L; Garin M; Vanlandingham R; Brusselle G
    Lancet Respir Med; 2020 May; 8(5):461-474. PubMed ID: 32066536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
    Bjermer L; Lemiere C; Maspero J; Weiss S; Zangrilli J; Germinaro M
    Chest; 2016 Oct; 150(4):789-798. PubMed ID: 27056586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice.
    Wechsler ME; Peters SP; Hill TD; Ariely R; DePietro MR; Driessen MT; Terasawa EL; Thomason DR; Panettieri RA
    Chest; 2021 May; 159(5):1734-1746. PubMed ID: 33333058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
    Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
    Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Intravenous Reslizumab in Oral Corticosteroid-Dependent Asthma.
    Nair P; Bardin P; Humbert M; Murphy KR; Hickey L; Garin M; Vanlandingham R; Chanez P
    J Allergy Clin Immunol Pract; 2020 Feb; 8(2):555-564. PubMed ID: 31626990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis.
    Li J; Wang F; Lin C; Du J; Xiao B; Du C; Sun J
    J Asthma; 2017 Apr; 54(3):300-307. PubMed ID: 27435534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.
    Brusselle G; Germinaro M; Weiss S; Zangrilli J
    Pulm Pharmacol Ther; 2017 Apr; 43():39-45. PubMed ID: 28159511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
    Corren J; Weinstein S; Janka L; Zangrilli J; Garin M
    Chest; 2016 Oct; 150(4):799-810. PubMed ID: 27018175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy.
    Brusselle G; Canvin J; Weiss S; Sun SX; Buhl R
    ERJ Open Res; 2017 Jul; 3(3):. PubMed ID: 28845430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
    Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps.
    Weinstein SF; Katial RK; Bardin P; Korn S; McDonald M; Garin M; Bateman ED; Hoyte FCL; Germinaro M
    J Allergy Clin Immunol Pract; 2019 Feb; 7(2):589-596.e3. PubMed ID: 30193936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reslizumab in Eosinophilic Asthma: A Review.
    Deeks ED; Brusselle G
    Drugs; 2017 May; 77(7):777-784. PubMed ID: 28421429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma.
    Murphy K; Jacobs J; Bjermer L; Fahrenholz JM; Shalit Y; Garin M; Zangrilli J; Castro M
    J Allergy Clin Immunol Pract; 2017; 5(6):1572-1581.e3. PubMed ID: 29122156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.
    Castro M; Mathur S; Hargreave F; Boulet LP; Xie F; Young J; Wilkins HJ; Henkel T; Nair P;
    Am J Respir Crit Care Med; 2011 Nov; 184(10):1125-32. PubMed ID: 21852542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
    Han S; Kim S; Kim H; Suh HS
    Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
    Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.